semaglutide obesity phase 3 7·2 mg was modestly superior to placebo and 2·4 mg (#wegovy) for #WeightLoss in adults with obesity, while retaining a favourable risk–benefit profile. We recently had the lead author on the Semaglutide for the treatment of

Nutrire 49 , 26 (2024)

Comnmente se le conoce como el antioxidante maestro, por su papel crucial en la proteccin celular

Thyroid Cancer The FDA labels for Ozempic, Wegovy, Mounjaro, and Zepbound all include a black box warning about the risk of thyroid C-cell tumors

This disease of unknown origin is marked by the triad of polyostotic fibrous dysplasia, precocious puberty, and cutaneous pigmentation

Researchers based in the United Kingdom recently examined how GLP-1 agonist drugs impact asthma in people with obesity

The efficacy and safety of -nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial